BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 20525379)

  • 1. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
    Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
    Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
    Li Z; Zhu Q; Chen H; Hu L; Negi H; Zheng Y; Ahmed Y; Wu Z; Li D
    Cancer Lett; 2016 Jul; 377(1):32-43. PubMed ID: 27063095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
    Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM
    J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
    Fernandez-Cuesta L; Anaganti S; Hainaut P; Olivier M
    Int J Cancer; 2011 Apr; 128(8):1813-21. PubMed ID: 20549698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.
    Wright TM; Wardell SE; Jasper JS; Stice JP; Safi R; Nelson ER; McDonnell DP
    Mol Cancer Res; 2014 Dec; 12(12):1829-39. PubMed ID: 25100862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
    Ikeda H; Taira N; Hara F; Fujita T; Yamamoto H; Soh J; Toyooka S; Nogami T; Shien T; Doihara H; Miyoshi S
    Breast Cancer Res; 2010; 12(3):R43. PubMed ID: 20579400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
    Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
    Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
    Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
    Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ShRNA-mediated gene silencing of MTA1 influenced on protein expression of ER alpha, MMP-9, CyclinD1 and invasiveness, proliferation in breast cancer cell lines MDA-MB-231 and MCF-7 in vitro.
    Jiang Q; Zhang H; Zhang P
    J Exp Clin Cancer Res; 2011 May; 30(1):60. PubMed ID: 21595884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.
    Kannan N; Kang J; Kong X; Tang J; Perry JK; Mohankumar KM; Miller LD; Liu ET; Mertani HC; Zhu T; Grandison PM; Liu DX; Lobie PE
    Neoplasia; 2010 Dec; 12(12):1041-53. PubMed ID: 21170268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker.
    Salmans ML; Zhao F; Andersen B
    Breast Cancer Res; 2013 Apr; 15(2):204. PubMed ID: 23635006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
    Jansen GH; Franke HR; Wolbers F; Brinkhuis M; Vermes I
    Climacteric; 2008 Aug; 11(4):315-21. PubMed ID: 18645697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors.
    Cañas A; López-Sánchez LM; Valverde-Estepa A; Hernández V; Fuentes E; Muñoz-Castañeda JR; López-Pedrera C; De La Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
    Breast Cancer Res; 2012 Dec; 14(6):R153. PubMed ID: 23216744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells.
    Kilker RL; Planas-Silva MD
    Cancer Res; 2006 Dec; 66(23):11478-84. PubMed ID: 17145896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
    Hoffman KL; Lerner SP; Smith CL
    Horm Cancer; 2013 Feb; 4(1):24-35. PubMed ID: 22965848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.
    Zhang X; Ding L; Kang L; Wang ZY
    PLoS One; 2012; 7(1):e30174. PubMed ID: 22276155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M; Jiang D; Hinsch C; Fan W
    Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.
    Nehra R; Riggins RB; Shajahan AN; Zwart A; Crawford AC; Clarke R
    FASEB J; 2010 Jun; 24(6):2040-55. PubMed ID: 20154269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells.
    Watts CK; Sweeney KJ; Warlters A; Musgrove EA; Sutherland RL
    Breast Cancer Res Treat; 1994; 31(1):95-105. PubMed ID: 7981461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
    Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM
    Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.